RESUMO
Introdução: A Síndrome Stevens-Johnson (SSJ) é uma doença causada por hipersensibilidade a imunocomplexos e pode ser desencadeada por distintos fármacos, dentre eles a fenitoína. Devido sua complexidade e raridade, ainda nãohá consenso de tratamento padrão ouro, porém sabese da necessidade da atuação multidisciplinar. Para os cuidados com as feridas, pode-se citar os curativo se a fotobiomodulação (FBM). Objetivo: Relatar o uso da FBM como terapia complementar em um caso de SSJ no Hospital Universitário Regional dos Campos Gerais (HU-UEPG). Métodos: Paciente sexo feminino, 26 anos, deu entrada na unidade de terapia intensiva (UTI) com diagnóstico de SSJ secundária ao uso de fenitonína, escore de SCORTEN 1, com área sem epitélio íntegro 10- 30% e área acometida por lesões de 94,5%, poupando apenas o couro cabeludo. Foi abordada e tratada por uma equipe multidisciplinar e solicitado vaga em centro de especializado em queimados. No sétimo dia de UTI foi iniciado tratamento com FBM, 2 J por ponto, distância entre pontos de 2cm, comprimento onda vermelho (660nm), nas feridas que não apresentavam secreção, foram cinco sessões com intervalo de três dias entre a terceira e a quarta. Resultados: A paciente apresentou melhora visível das lesões cutâneas e recebeu alta hospitalar 5 dias após cessação da FBM. Conclusão: O uso da FBM pode ser efetiva no tratamento complementar da fase aguda SSJ desencadeada por fenitoína.
Introduction: Stevens-Johnson Syndrome (SJS) is a disease caused by hypersensitivity to immune complexes and can be triggered by different drugs, including phenytoin. Due to its complexity and rarity, there is still no consensus on gold standard treatment, but the need for multidisciplinary action is known. For wound care, dressings and photobiomodulation (PBM) can be mentioned. Objective: This study is to report the use of PBM as complementary therapy in a case of SJS at Hospital Universitário Regional dos Campos Gerais (HU-UEPG). Methods: A 26-year-old female patient was admitted to the intensive care unit (ICU) diagnosed with SJS secondary to the use of phenytoin, SCORTEN score 1, with an area without intact epithelium 10-30% and an area affected by injuries of 94.5 %, saving only the scalp. She was approached and treated by a multidisciplinary team which requested a place in a specialized burn center. On the seventh day of ICU, treatment with PBM, 2J per point was started, distance between points of 2cm, red wave length (660nm), in wounds that did not present secretion, with a total of five sessions with an interval of three days between the third and fourth. Results: The patient showed a visible improvement of skin lesions and was discharged from hospital 5 days after cessation of PBM. Conclusion: Use of PBM can be effective in complementary treatment of acute SJS phase triggered by phenytoin.
Assuntos
Humanos , Feminino , Adulto , Síndrome de Stevens-Johnson , Terapia com Luz de Baixa Intensidade , Fenitoína , Couro Cabeludo , Ferimentos e Lesões , Modalidades de Fisioterapia , Doenças do Complexo ImuneRESUMO
Los procesos inmunitarios son utilizados por el organismo para defenderse de la agresión de agentes infecciosos; no obstante, en ciertos casos, el organismo reacciona de forma inapropiada o excesiva ocasionando diversos tipos de daño tisular. Estas situaciones, que conocemos como hipersensibilidad, pueden tener aspectos positivos o negativos al poder causar ellos mismos la enfermedad. Se presenta el caso de una niña de 14 años de edad, que acude al Hospital Pediátrico Docente William Soler después de varios ingresos en otros centros de salud, donde se planteó el diagnóstico de un pie de madura. Después de varias investigaciones y con el antecedente de alergia a diferentes medicamentos, los cuadros de amigdalitis a repetición, los datos del laboratorio y la clínica que presentaba la paciente, se estableció el diagnóstico de una vasculitis por reacción de hipersensibilidad tipo III. Por las características tan atípicas del cuadro clínico de esta paciente y la dificultad para llegar a un diagnóstico es importante la presentación de este caso(AU)
The immune processes are used by the body to defend against the aggression of infectious agents; however, in certain cases, the body reacts inappropriately or excessively causing various types of tissue damage. These situations, which we know as hypersensitivity, can have positive or negative aspects by being able to cause the disease themselves. We present the case of a 14-year-old girl who attended the William Soler Pediatric Teaching Hospital after several admissions to other health centers, where the diagnosis of a mature foot was raised. After several investigations and with the history of allergy to different drugs, the recurrent tonsillitis symptoms, the laboratory data and the clinic presented by the patient, the diagnosis of a vasculitis due to type III hypersensitivity reaction was established. Because of the atypical characteristics of this patient's clinical picture and the difficulty in reaching a diagnosis, the presentation of this case is important(AU)
Assuntos
Feminino , Adolescente , Vasculite/etiologia , Doenças do Complexo Imune/diagnósticoRESUMO
Mac-1 (CD11b/CD18) is a ß2 integrin classically regarded as a pro-inflammatory molecule because of its ability to promote phagocyte cytotoxic functions and enhance the function of several effector molecules such as FcγR, uPAR, and CD14. Nevertheless, recent reports have revealed that Mac-1 also plays significant immunoregulatory roles, and genetic variants in ITGAM, the gene that encodes CD11b, confer risk for the autoimmune disease systemic lupus erythematosus (SLE). This has renewed interest in the physiological roles of this integrin and raised new questions on how its seemingly opposing biological functions may be regulated. Here, we provide an overview of the CD18 integrins and how their activation may be regulated as this may shed light on how the opposing roles of Mac-1 may be elicited. We then discuss studies that exemplify Mac-1's pro-inflammatory versus regulatory roles particularly in the context of IgG immune complex-mediated inflammation. This includes a detailed examination of molecular mechanisms that could explain the risk-conferring effect of rs1143679, a single nucleotide non-synonymous Mac-1 polymorphism associated with SLE.
Assuntos
Antígeno CD11b/metabolismo , Doenças do Complexo Imune/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Animais , Antígeno CD11b/genética , Predisposição Genética para Doença , Humanos , Imunomodulação , Fagocitose , Polimorfismo Genético , RiscoRESUMO
INTRODUCTION: Colombia is the country in America with the highest proportion of new cases leprosy with severe disability. To decrease such disability it is necessary to control these reactions, the main cause of nerve damage in leprosy. OBJECTIVE: To describe the clinical and epidemiological characteristics and the treatment of patients with type 1 and 2 leprosy reactions who consulted the Centro Dermatológico Federico Lleras Acosta. MATERIALS AND METHODS: It is a descriptive study which included patients with clinical diagnoses of type 1 and 2 reactions who were seen in the center between 2003 and 2009. The town of origin of the patients, their age, clinical features and treatments were analysed. RESULTS: We studied 96 reactions in 87 patients, 35 type 1 and 61 type 2 reactions; 75% of the patients came from the departments of Tolima, Cundinamarca, Santander and Boyacá; 77% of type 1 reaction occurred before the beginning of multidrug therapy for leprosy. The reactions that started after stopping the multidrug therapy were considered as a leprosy relapse. CONCLUSIONS: Correct identification of type 1 reaction by the general practitioner will allow the diagnosis of leprosy in a large percentage of patients. The type 1 reaction that begins after stopping the leprosy multidrug therapy may be a manifestation of a relapse of the disease.
Assuntos
Eritema Nodoso/epidemiologia , Hanseníase/patologia , Adolescente , Adulto , Idoso , Colômbia/epidemiologia , Citocinas/metabolismo , Quimioterapia Combinada , Eritema Nodoso/etiologia , Feminino , Humanos , Doenças do Complexo Imune/epidemiologia , Doenças do Complexo Imune/etiologia , Hansenostáticos/uso terapêutico , Hanseníase/tratamento farmacológico , Hanseníase/epidemiologia , Hanseníase/fisiopatologia , Hanseníase Virchowiana/complicações , Hanseníase Virchowiana/tratamento farmacológico , Hanseníase Virchowiana/epidemiologia , Hanseníase Virchowiana/imunologia , Hanseníase Paucibacilar/tratamento farmacológico , Hanseníase Paucibacilar/patologia , Hanseníase Paucibacilar/fisiopatologia , Masculino , Pessoa de Meia-Idade , Recidiva , Centros de Atenção Terciária/estatística & dados numéricos , Adulto JovemRESUMO
Introducción. Colombia es el país de América con mayor proporción de casos nuevos de lepra con discapacidad grave. Para disminuir tal discapacidad se requiere el control de las reacciones, principal causa del daño neural en esta enfermedad. Objetivo. Describir las características clínicas y epidemiológicas y el tratamiento de los pacientes con reacciones de tipo 1 y 2 que consultaron al Centro Dermatológico Federico Lleras Acosta. Materiales y métodos. Se trata de un estudio descriptivo que incluyó la población de pacientes con diagnóstico clínico de reacciones de tipo 1 y de tipo 2 por lepra, que acudieron al centro entre los años 2003 y 2009. Resultados. Se estudiaron 96 reacciones, 35 del tipo 1 y 61 del tipo 2. El 75 % de los pacientes provenía de los departamentos de Tolima, Cundinamarca, Santander y Boyacá. El 56 % de las reacciones de tipo 1 se presentaron antes de iniciar la poliquimioterapia para la lepra; el dermatólogo tratante consideró que las reacciones que se presentaron después de suspender la poliquimioterapia eran recaídas. El 94 % de las reacciones de tipo 1 se trataron con corticoides orales. El 97 % de los pacientes con reacciones de tipo 2 presentaron eritema nudoso, y todos se trataron con talidomida. Conclusiones.La clínica de la reacción de tipo 1 puede orientar al diagnóstico de la lepra en un paciente sin el antecedente de esta enfermedad (56 %). La reacción de tipo 1 que se inicia después de suspender la poliquimioterapia para la lepra, podría ser una manifestación de recaída de la enfermedad. La reacción de tipo 2 es más frecuente en hombres, con una relación hombre a mujer de 4:1. El 97 % de los pacientes con reacción de tipo 2 presentó eritema nudoso.
Introduction: Colombia is the country in America with the highest proportion of new cases leprosy with severe disability. To decrease such disability it is necessary to control these reactions, the main cause of nerve damage in leprosy. Objective: To describe the clinical and epidemiological characteristics and the treatment of patients with type 1 and 2 leprosy reactions who consulted the Centro Dermatológico Federico Lleras Acosta. Materials and methods: It is a descriptive study which included patients with clinical diagnoses of type 1 and 2 reactions who were seen in the center between 2003 and 2009. The town of origin of the patients, their age, clinical features and treatments were analysed. Results: We studied 96 reactions in 87 patients, 35 type 1 and 61 type 2 reactions; 75% of the patients came from the departments of Tolima, Cundinamarca, Santander and Boyacá; 77% of type 1 reaction occurred before the beginning of multidrug therapy for leprosy. The reactions that started after stopping the multidrug therapy were considered as a leprosy relapse. Conclusions: Correct identification of type 1 reaction by the general practitioner will allow the diagnosis of leprosy in a large percentage of patients. The type 1 reaction that begins after stopping the leprosy multidrug therapy may be a manifestation of a relapse of the disease.
Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Eritema Nodoso/epidemiologia , Hanseníase/patologia , Colômbia/epidemiologia , Citocinas , Quimioterapia Combinada , Eritema Nodoso/etiologia , Doenças do Complexo Imune/epidemiologia , Doenças do Complexo Imune/etiologia , Hansenostáticos/uso terapêutico , Hanseníase Virchowiana/complicações , Hanseníase Virchowiana/tratamento farmacológico , Hanseníase Virchowiana/epidemiologia , Hanseníase Virchowiana/imunologia , Hanseníase Paucibacilar/tratamento farmacológico , Hanseníase Paucibacilar/patologia , Hanseníase Paucibacilar/fisiopatologia , Hanseníase/tratamento farmacológico , Hanseníase/epidemiologia , Hanseníase/fisiopatologia , Recidiva , Centros de Atenção Terciária/estatística & dados numéricosRESUMO
Immune complex (IC) deposition in tissues triggers the release of harmful oxidant and lytic compounds by neutrophils. We examined how ten 3-phenylcoumarin derivatives affect the reactive oxygen species (ROS) production by IC-stimulated human neutrophils. Most of the 3-phenylcoumarins inhibited the luminol-enhanced chemiluminescence (CL-lum) more strongly than they inhibited the lucigenin-enhanced chemiluminescence (CL-luc), without clear signs of toxicity. The most effective CL-lum inhibitors, 6,7-dihydroxy-3-[3',4'-methylenedioxyphenyl]-coumarin (5) and 6,7-dihydroxy-3-[3',4'-dihydroxyphenyl]-coumarin (19), also inhibited myeloperoxidase activity more potently and had higher hypochlorous acid scavenging ability, but did not affect the NADPH-oxidase activity. The type, number, and position of the substituent influenced the pharmacological effects of 3-phenylcoumarins; however, the structural requirements for CL-lum and CL-luc inhibition were a little different. Compounds 5 and 19 are promising prototypes of therapeutic molecules to modulate ROS production by neutrophils in IC-mediated inflammatory diseases.
Assuntos
Cumarínicos/farmacologia , Sequestradores de Radicais Livres/farmacologia , Neutrófilos/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Complexo Antígeno-Anticorpo/imunologia , Células Cultivadas , Cumarínicos/química , Descoberta de Drogas , Sequestradores de Radicais Livres/química , Humanos , Doenças do Complexo Imune/imunologia , Imunomodulação , Medições Luminescentes , Terapia de Alvo Molecular , Neutrófilos/imunologia , Oxirredução/efeitos dos fármacos , Peroxidase/metabolismo , Relação Estrutura-AtividadeRESUMO
Schistosomiasis or bilharzia is a parasitic disease found in tropical countries. Most infections are subclinical but may progress to chronic form characterized most frequently by the presence of liver involvement and portal hypertension. We report a patient that presented chronic polyarthritis with positive rheumatoid factor. During investigation, increased liver enzymes, negative hepatitis serologies and signs of portal hypertension on an ultrasound examination raised suspicion of S. mansoni infection. We will discuss pathophysiology and clinical manifestations of S. mansoni infection with special attention to articular involvement.
Assuntos
Artrite/imunologia , Doenças do Complexo Imune/imunologia , Esquistossomose mansoni/imunologia , Adulto , Alanina Transaminase/sangue , Artrite/sangue , Artrite/diagnóstico , Artrite/parasitologia , Aspartato Aminotransferases/sangue , Biomarcadores/sangue , Doença Crônica , Feminino , Articulação da Mão/diagnóstico por imagem , Humanos , Hipertensão Portal/diagnóstico por imagem , Hipertensão Portal/imunologia , Hipertensão Portal/parasitologia , Doenças do Complexo Imune/sangue , Doenças do Complexo Imune/diagnóstico , Doenças do Complexo Imune/parasitologia , Praziquantel/uso terapêutico , Valor Preditivo dos Testes , Radiografia , Fator Reumatoide/sangue , Esquistossomose mansoni/sangue , Esquistossomose mansoni/diagnóstico , Esquistossomose mansoni/tratamento farmacológico , Esquistossomose mansoni/parasitologia , Esquistossomicidas/uso terapêutico , Resultado do Tratamento , UltrassonografiaRESUMO
O teste do Fator Antinúcleo (FAN) é um importante teste para triagem de doenças autoimunes, porém outras condições clínicas alteram esse exame. Ademais, poucos clínicos e generalistas sabem avaliar o seu resultado e, em consequência disso, revisamos como o teste deve ser usado na prática clínica.
The Test for Antinuclear Antibodies (ANA) is a very important factor in the evaluation of autoimmune diseases, however the test can be positive in other conditions in clinical practice, furthermore few generalists and physicians know how to use the results of the test, thereby we reviewed how to correctly use the test in everyday clinical practice.
Assuntos
Reumatologia , Imunofluorescência , Doenças do Complexo Imune/diagnósticoRESUMO
La enfermedad del suero es una enfermedad alérgica rara que se produce por la administración de material antigénico exógeno. Históricamente causada por suero heterólogo; corresponde a una reacción de hipersensibilidad tipo III mediada por depósitos de complejos inmunes circulantes en los pequeños vasos sanguíneos, la cual induce la activación del complemento y subsecuente inflamación. Las características clínicas son fiebre, erupción cutánea, artralgias y linfadenopatías, pudiendo llegar a producir glomerulonefritis o compromiso de otro órgano. Presentamos el caso de un paciente que desarrolló enfermedad del suero posterior a la administración de suero antiofídico.
Serum sickness is a rare allergic disease, produced by the administration of exogenous antigenic material. Historically caused by heterologous serum, it corresponds to a type III hypersensitivity reaction mediated by deposits of circulating immune complexes in small blood vessels, which induces complement activation and subsequent inflammation. Clinical features are fever, rash, arthralgia and lymphadenopathy; this pathology may lead to glomerulonephritis or other organ involvement. We report a patient who developed serum sickness after antivenom administration.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Doença do Soro , Doenças do Complexo Imune , SoroRESUMO
Here, we report the occurrence of leukocytoclastic vasculitis as an outcome of type III allergy to insulin in a patient with type II diabetes mellitus. The diagnosis was made on the basis of anatomo-pathological examination of a skin biopsy.
Assuntos
Hipersensibilidade/complicações , Doenças do Complexo Imune/complicações , Insulina/imunologia , Vasculite Leucocitoclástica Cutânea/diagnóstico , Vasculite Leucocitoclástica Cutânea/etiologia , Adulto , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/imunologia , Humanos , MasculinoRESUMO
BACKGROUND: Immune complex deposition is the accepted mechanism of pathogenesis of VL glomerulopathy however other immune elements may participate. Further in the present study, no difference was seen between immunoglobulin and C3b deposit intensity in glomeruli between infected and non-infected dogs thus T cells, adhesion molecules and parameters of proliferation and apoptosis were analysed in dogs with naturally acquired VL from an endemic area. The dog is the most important domestic reservoir of the protozoa Leishmania (L.) chagasi that causes visceral leishmaniasis (VL). The similarity of VL manifestation in humans and dogs renders the study of canine VL nephropathy of interest with regard to human pathology. METHODS: From 55 dogs with VL and 8 control non-infected dogs from an endemic area, kidney samples were analyzed by immunohistochemistry for immunoglobulin and C3b deposits, staining for CD4+ and CD8+ T cells, ICAM-1, P-selectin and quantified using morphometry. Besides proliferation marker Ki-67, apoptosis markers M30 and TUNEL staining, and related cytokines TNF-alpha, IL-1alpha were searched and quantified. RESULTS: We observed similar IgG, IgM and IgA and C3b deposit intensity in dogs with VL and non-infected control dogs. However we detected the Leishmania antigen in cells in glomeruli in 54, CD4+ T cells in the glomeruli of 44, and CD8+ T cells in 17 of a total of 55 dogs with VL. Leishmania antigen was absent and T cells were absent/scarse in eight non-infected control dogs. CD 4+ T cells predominate in proliferative patterns of glomerulonephritis, however the presence of CD4+ and CD8+ T cells were not different in intensity in different patterns of glomerulonephritis. The expression of ICAM-1 and P-selectin was significantly greater in the glomeruli of infected dogs than in control dogs. In all patterns of glomerulonephritis the expression of ICAM-1 ranged from minimum to moderately severe and P-selectin from absent to severe. In the control animals the expression of these molecules ranged from absent to medium intensity. It was not observed any correlation between severity of the disease and these markers. There was a correlation between the number of Leishmania antigen positive cells and CD4+ T cells, and between the number of CD4+ T cells and CD8+ T cells. In dogs presenting different histopathological patterns of glomerulonephritis, parameters of proliferation and apoptosis were studied. Ki-67, a proliferative marker, was not detected locally, but fewer apoptotic cells and lower TNF-alpha expression were seen in infected animals than in non-infected controls. CONCLUSION: Immunopathogenic mechanisms of VL glomerulonephritis are complex and data in the present study suggest no clear participation of immunoglobulin and C3b deposits in these dogs but the possible migration of CD4+ T cells into the glomeruli, participation of adhesion molecules, and diminished apoptosis of cells contributing to determine the proliferative pattern of glomerulonephritis in VL.
Assuntos
Apoptose , Linfócitos T CD4-Positivos/imunologia , Moléculas de Adesão Celular/imunologia , Doenças do Cão/imunologia , Glomerulonefrite/imunologia , Leishmaniose Visceral/veterinária , Animais , Cães , Doenças do Complexo Imune/imunologia , Imuno-Histoquímica , Rim/patologia , Leishmania infantum/imunologia , Leishmaniose Visceral/complicações , Leishmaniose Visceral/imunologia , MicroscopiaRESUMO
Tissue damage in autoimmune diseases involves excessive production of reactive oxygen species (ROS) triggered by immune complexes (IC) and neutrophil (PMN) interactions via receptors for the Fc portion of IgG (FcgammaR) and complement receptors (CR). Modulation of both the effector potential of these receptors and ROS generation may be relevant to the maintenance of body homeostasis. In the present study, the modulatory effect of four flavonols (myricetin, quercetin, kaempferol, galangin) on rabbit PMN oxidative metabolism, specifically stimulated via FcgammaR, CR or both classes of receptors, was evaluated by luminol- and lucigenin-dependent chemiluminescence assays. Results showed that flavonol inhibitory effect was not dependent on the cell membrane receptor class stimulated but related to the lipophilicity of the compounds (their apparent partition coefficient values were obtained by high-performance liquid chromatography), and was also inversely related to the number of hydroxyl groups in the flavonol B ring and the ROS-scavenger activity (assessed by the luminol--H2O2--horseradish peroxidase reaction). Under the experimental conditions the flavonols tested were not toxic to PMNs (evaluated by lactate dehydrogenase release and trypan blue exclusion) and did not interfere with IC-induced phagocytosis (evaluated by transmission electron microscopy). Our results suggested that inhibition of IC-stimulated PMNs effector functions by the flavonols tested herein was the result of cooperation of different cellular mechanisms.
Assuntos
Derivados de Benzeno/farmacologia , Flavonóis/farmacologia , Fatores Imunológicos/química , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Receptores de Complemento/metabolismo , Receptores Fc/metabolismo , Acridinas/química , Animais , Complexo Antígeno-Anticorpo/imunologia , Complexo Antígeno-Anticorpo/metabolismo , Derivados de Benzeno/química , Derivados de Benzeno/metabolismo , Proteínas do Sistema Complemento/metabolismo , Flavonoides/química , Flavonoides/metabolismo , Flavonoides/farmacologia , Flavonóis/química , Flavonóis/metabolismo , Sequestradores de Radicais Livres/química , Sequestradores de Radicais Livres/metabolismo , Sequestradores de Radicais Livres/farmacologia , Interações Hidrofóbicas e Hidrofílicas , Hidroxilação , Doenças do Complexo Imune/tratamento farmacológico , Doenças do Complexo Imune/metabolismo , Fatores Imunológicos/metabolismo , Quempferóis/química , Quempferóis/metabolismo , Quempferóis/farmacologia , Medições Luminescentes , Luminol/química , Estrutura Molecular , Neutrófilos/imunologia , Oxirredução/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Fagocitose/imunologia , Quercetina/química , Quercetina/metabolismo , Quercetina/farmacologia , Coelhos , Receptores de Complemento/imunologia , Receptores Fc/imunologia , Relação Estrutura-AtividadeRESUMO
OBJECTIVE: The aim of this study was to investigate if low-level laser therapy (LLLT) can modulate formation of hemorrhagic lesions induced by immune complex. BACKGROUND DATA: There is a lack of information on LLLT effects in hemorrhagic injuries of high perfusion organs, and the relative efficacy of LLLT compared to anti-inflammatory drugs. METHODS: A controlled animal study was undertaken with 49 male Wistar rats randomly divided into seven groups. Bovine serum albumin (BSA) i.v. was injected through the trachea to induce an immune complex lung injury. The study compared the effect of irradiation by a 650-nm Ga-Al-As laser with LLLT doses of 2.6 Joules/cm(2) to celecoxib, dexamethasone, and control groups for hemorrhagic index (HI) and myeloperoxide activity (MPO) at 24 h after injury. RESULTS: The HI for the control group was 4.0 (95% CI, 3.7-4.3). Celecoxib, LLLT, and dexamethasone all induced significantly (p < 0.01) lower HI than control animals at 2.5 (95% CI, 1.9-3.1), 1.8 (95% CI, 1.2-2.4), and 1.5 (95% CI, 0.9-2.1), respectively, for all comparisons to control. Dexamethasone, but not celecoxib, induced a slightly, but significantly lower HI than LLLT (p = 0.04). MPO activity was significantly decreased in groups receiving celecoxib at 0.87 (95% CI, 0.63-1.11), dexamethasone at 0.50 (95% CI, 0.24-0.76), and LLLT at 0.7 (95% CI, 0.44-0.96) when compared to the control group, at 1.6 (95% CI, 1.34-1.96; p < 0.01), but there were no significant differences between any of the active treatments. CONCLUSION: LLLT at a dose of 2.6 Joules/cm(2) induces a reduction of HI levels and MPO activity in hemorrhagic injury that is not significantly different from celecoxib. Dexamethasone is slightly more effective than LLLT in reducing HI, but not MPO activity.
Assuntos
Hemorragia/radioterapia , Doenças do Complexo Imune/complicações , Terapia com Luz de Baixa Intensidade , Pneumopatias/radioterapia , Animais , Anti-Inflamatórios/farmacologia , Celecoxib , Dexametasona/farmacologia , Hemorragia/tratamento farmacológico , Hemorragia/etiologia , Pneumopatias/tratamento farmacológico , Pneumopatias/etiologia , Masculino , Pirazóis/farmacologia , Ratos , Ratos Wistar , Sulfonamidas/farmacologiaRESUMO
Antigen-antibody complexes can damage tissues by triggering inflammation. Recent studies have enabled the description of a sequence of steps, which depend on the intra- or perivascular location of complex formation. Acute lethal toxicity and circulatory shock as a result of the acute release of inflammatory mediators can occur after intravascular complex formation. The lesions associated with perivascular complexes are characterized by plasma leakage and the recruitment of polymorphonuclear leukocytes. These lesions are modulated by mediators released from endothelial cells, namely nitric oxide, endothelins and lipid mediators, and provide an appropriate basis for the activation of both arms of hemostasis: coagulation and fibrinolysis. The balance between both activation systems can explain the late occurrence of both tissue fibrosis and organ remodeling.
Assuntos
Complexo Antígeno-Anticorpo/imunologia , Endotélio Vascular/imunologia , Doenças do Complexo Imune/imunologia , Animais , Complexo Antígeno-Anticorpo/efeitos adversos , Endotélio Vascular/patologia , Fibrose , Humanos , Doenças do Complexo Imune/patologia , Modelos Biológicos , Receptores Fc/metabolismoAssuntos
Humanos , Hipersensibilidade , Hipersensibilidade Imediata/fisiopatologia , Eosinófilos/fisiologia , Doenças do Complexo Imune/fisiopatologia , Doenças do Sistema Imunitário/etiologia , Hipersensibilidade Tardia/fisiopatologia , Hipersensibilidade Tardia/classificação , Doenças Autoimunes/etiologia , Doenças Autoimunes/fisiopatologia , Síndrome da Imunodeficiência Adquirida , Síndromes de ImunodeficiênciaRESUMO
OBJECTIVE: The effect of bradykinin (B(1) or B(2)) receptor antagonists was studied in allergic and immune-complex-induced lung inflammation. METHODS: Lungs of BALB/c mice were examined 24 h after induction of lung inflammation, either allergic (ovalbumin-sensitized submitted to two aerosol of antigen, one week apart) or immune-complex induced (intratracheal instillation of IgG antibodies followed by intravenous antigen). The bradykinin B(2) receptor antagonist, HOE-140 or bradykinin B(1) receptor antagonist, R-954 were given intraperitoneally (100 microg/kg), 30 min before induction. RESULTS: In allergic inflammation, pre-treatment with R-954 reduced eosinophil infiltration into the lungs, mucus secretion and the airway hyperreactivity to methacholine. Pre-treatment with HOE-140 increased eosinophil infiltration but did not affect the other parameters. In immune-complex inflammation, HOE-140 increased neutrophil infiltration but not their activation nor the hemorrhagic lesions. R-594 pre-treatment did not change the parameters examined. CONCLUSION: These results show important modulatory effects of bradykinin B(1) and B(2) receptor antagonists in both models of lung inflammation.
Assuntos
Antagonistas dos Receptores da Bradicinina , Bradicinina/análogos & derivados , Hipersensibilidade , Doenças do Complexo Imune , Pneumonia/imunologia , Pneumonia/prevenção & controle , Animais , Bradicinina/uso terapêutico , Antagonistas de Receptor B1 da Bradicinina , Antagonistas de Receptor B2 da Bradicinina , Broncoconstrição/efeitos dos fármacos , Eosinófilos/patologia , Masculino , Cloreto de Metacolina/administração & dosagem , Camundongos , Camundongos Endogâmicos BALB C , Muco/metabolismo , Ovalbumina/imunologia , Pneumonia/patologiaAssuntos
Humanos , Masculino , Adulto , Feminino , Pessoa de Meia-Idade , Doença de Meniere , Orelha Média/fisiopatologia , Ciclosporina , Doenças do Complexo Imune , Doença de Meniere , Auxiliares de Audição , Desequilíbrio Hidroeletrolítico/etiologia , Desequilíbrio Hidroeletrolítico/imunologia , Distribuição por Idade , Distribuição por Sexo , Orelha Média/imunologiaRESUMO
OBJECTIVE: The goals of the current work are: 1) to examine the epidermal deposition of anti-RNP IgG human autoantibodies in neonatal BALB/c mice; 2) to look for immunoregulatory effects of anti-idiotypes allowing one to inhibit the epidermal deposition of anti-RNP antibodies; and 3) to elicit antinuclear antibodies in adult BALB/c mice by internal images of anti-idiotypes. MATERIALS AND METHODS: Anti-idiotype antibodies were produced with human anti-RNP IgG obtained by ion exchange chromatography; F(ab')2 fragments were recovered from pepsin digestion and were purified using Sephacryl S-300. F(ab')2 fragments were then used to immunize New Zealand rabbits. RESULTS: The anti-RNP IgG recognized the 70 kDa protein and the A (31 kDa) and C (19 kDa) proteins, while the anti-idiotype antibody specifically recognized the light or heavy chain of the anti-RNP (Fab')2 fragments. Additionally, anti-idiotypes recognized the anti-RNP IgG from some sera, but not the IgG from other specificities or from normal IgG. When anti-RNP IgG was injected intraperitoneally into BALB/c mice it induced immune complex deposition in the epidermis and at the dermal-epidermal junction. Previous injection of anti-idiotype antibodies abrogated the anti-RNP IgG deposits. Vaccination with anti-idiotypes elicit antinuclear antibodies in adult BALB/c mice. CONCLUSIONS: Anti-idiotype antibodies abrogate in vitro the antinuclear antibody deposition in neonatal BALB/c mice. Anti-idiotype antibodies elicit antinuclear antibodies in adult BALB/c mice.